BioPharma Dive - Latest News

iTeos, GSK to shelve TIGIT drug after study setback

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic review in response. 

May 13, 2025 - 16:24
 0
iTeos, GSK to shelve TIGIT drug after study setback

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic review in response. 

Read More

Tags:

Previous Article

Fierce Biotech Layoff Tracker 2025: Leap halves team; Atara lays off 30% of staf...

Next Article

FDA Begins Action To Remove Ingestible Fluoride Prescription Drug Products for C...

Related Posts

Facing ‘uncertainty on steroids,’ biotech dealmakers tread more cautiously

Facing ‘uncertainty on steroids,’ biotech dealmakers tr...

May 6, 2025  0

Sarepta shares plummet as lower sales outlook adds to gloom over FDA’s new biologics hire

Sarepta shares plummet as lower sales outlook adds to g...

May 7, 2025  0

Bluebird pleads for deal support; Unity, Mersana lay off staff

Bluebird pleads for deal support; Unity, Mersana lay of...

May 6, 2025  0